Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04601233 · ClinicalTrials.gov registry record · Phase 4
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
A Phase 4 study, sponsored by Tulane University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04601233: Clinical Trial Phase 4 study, sponsored by Tulane University.
NCT04601233 is a Phase 4 study that has not yet begun recruiting, run by Tulane University. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04601233, a Phase 4 study, has not yet begun recruiting, sponsored by Tulane University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effects of testosterone treatment on erectile function, fatigue, depression, cognitive function, quality of life, urinary incontinence, pain, and damage to neurons in male Multiple Sclerosis patients with low testosterone, using questionnaires, blood samples and a rectal exam in volunteers 55 years and older.
Primary Outcome
Androgen Deficiency in the Aging Male (ADAM score) includes ten "Yes or No" questions, with an answer "Yes" to number 1 or 7 or if you answer "Yes" to more than 3 questions, you may have low Testosterone.
Interventions
- DRUG XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What is known before NCT04601233 opens enrollment
NCT04601233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector is the first listed.
NCT04601233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04601233 about?
NCT04601233 is a clinical study titled "Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis". The purpose of the study is to determine the effects of testosterone treatment on erectile function, fatigue, depression, cognitive function, quality of life, urinary incontinence, pain, and damage to neurons in male Multiple Sclerosis patients with low testosterone, using questionnaires, blood samp...
What is the current status of trial NCT04601233?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-06. Estimated completion is 2026-12.
What interventions are being tested in trial NCT04601233?
The interventions under investigation include: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector (DRUG).
Who is sponsoring clinical trial NCT04601233?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04601233's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia